946387-07-1

RN 1734 is a novel TRPV4 modulator.

RN-1734 has been used as a transient receptor potential vanilloid 4 (TRPV4) blocker to study its effects on differentiation of a corneal epithelial cell model, RCE1(5T5) cells.

A cell-permeable benzenesulfonamide compound that acts as a selective TRPV4 antagonist and inhibits TRPV4 agonist 4α-PDD- (Cat. No. 524394) stimulated Ca²⁺ influx (IC₅₀ = 2.3, 3.2 and 5.9 μM, respectively, in HEK293 expressing human, rat, or mouse TRPV4) without affecting the activity of three other human TRP (transient receptor potential) channels, including capsaicin- (Cat. No. 211275) activated TRPV1, camphor-activated TRPV3, and methanol-activated TRPM8 (IC₅₀ >30 μM).

Selective TRPV4 antagonist (IC 50 values are 2.3, 5.9 and 3.2 μ M for hTRPV4, mTRPV4 and rTRPV4 receptors respectively). Displays selectivity for over other TRP channels (IC 50 values are 2.3, >30, >30 and >100 μ M for TRPV4, TRPV3, TRPM8 and TRPV1 respectively).

RN-1734 is a selective TRPV4 antagonist.

Store at -20°C